Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Venous Retinal Branch Occlusion Clear all
Not listed Phase 1 Interventional Accepts healthy volunteers

Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion

NCT01011374
View directory record Official record
Conditions
Venous Retinal Branch Occlusion, Central Retinal Vein Occlusion, Retinal Vein Occlusion, Depression
Interventions
ranibizumab (Lucentis)
Drug
Lead sponsor
Retina Associates of Cleveland, Inc
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 17, 2011 · Synced Jul 21, 2026, 7:38 PM EDT
Not listed Phase 1 Interventional

Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

NCT04120636
View directory record Official record
Conditions
Macula Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane, Central Serous Retinopathy With Pit of Optic Disc, Commotio Retinae, Vitritis
Interventions
Episcleral Celecoxib
Drug
Lead sponsor
Targeted Therapy Technologies, LLC
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2023 · Synced Jul 21, 2026, 7:38 PM EDT
Not listed Phase 1 Interventional

Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

NCT04120311
View directory record Official record
Conditions
Macular Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane, Central Serous Retinopathy With Pit of Optic Disc, Commotio Retinae, Vitritis
Interventions
Episcleral Dexamethasone
Drug
Lead sponsor
Targeted Therapy Technologies, LLC
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2023 · Synced Jul 21, 2026, 7:38 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)

NCT01521559
View directory record Official record
Conditions
Branch Retinal Vein Occlusion
Interventions
Macular Laser Photocoagulation, Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
Procedure · Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
45
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2014 · Synced Jul 21, 2026, 7:38 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusions

NCT00500045
View directory record Official record
Conditions
Central Retinal Vein Occlusion, Branch Retinal Vein Occlusion
Interventions
nicotinic acid
Drug
Lead sponsor
Palo Alto Medical Foundation
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Jul 21, 2026, 7:38 PM EDT
Recruiting Phase 2 Interventional

A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO

NCT07205887
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
Interventions
EYE103, Aflibercept 2.0 mg
Drug
Lead sponsor
EyeBiotech Ltd.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
49
States / cities
Scottsdale, Arizona • Glendale, California • Modesto, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 21, 2026, 7:38 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)

NCT05127525
View directory record Official record
Conditions
Diabetic Macular Edema, Branch Retinal Vein Occlusion, Glaucoma/Closed Angle Glaucoma
Interventions
IRX-101, Control
Drug
Lead sponsor
iRenix Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Jul 21, 2026, 7:38 PM EDT
Completed Phase 4 Interventional Results available

Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO

NCT02503540
View directory record Official record
Conditions
Retinal Vein Occlusion, Diabetic Macular Edema, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion
Interventions
Aflibercept
Drug
Lead sponsor
Justis Ehlers
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Jul 21, 2026, 7:38 PM EDT
Completed Phase 1 Interventional

Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders

NCT00101764
View directory record Official record
Conditions
Macular Degeneration, Retinal Vein Occlusion, Diabetic Retinopathy
Interventions
Triamcinolone Acetonide
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 21, 2026, 7:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study

NCT02390245
View directory record Official record
Conditions
Glaucoma, Glaucoma Suspect, Diabetic Retinopathy, Ocular Hypertension, Cataract, Branch Retinal Vein Occlusion, Branch Retinal Arterial Occlusion, Central Retinal Vein Occlusion, Central Retinal Artery Occlusion, Epi-retinal Membrane, Macular Degeneration, Drusen, Loss of Vision
Interventions
Free Eye Screenings, Enhanced Intervention, Usual Care
Other
Lead sponsor
Wills Eye
Other
Eligibility
40 Years and older
Enrollment
906 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Jul 21, 2026, 7:38 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion

NCT00406107
View directory record Official record
Conditions
Branch Retinal Vein Occlusion
Interventions
pegaptanib sodium (Macugen)
Drug
Lead sponsor
Palmetto Retina Center, LLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Los Angeles, California • Hagerstown, Maryland • West Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Jul 21, 2026, 7:38 PM EDT
Active, not recruiting No phase listed Observational

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

NCT05476926
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Hemi-retinal Vein Occlusion
Interventions
Faricimab, Port Delivery System with Ranibizumab
Drug · Combination Product
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
18
States / cities
Phoenix, Arizona • Pasadena, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jul 21, 2026, 7:38 PM EDT
Terminated Phase 3 Interventional Results available

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

NCT03810313
View directory record Official record
Conditions
Central Retinal Vein Occlusion
Interventions
Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
30
States / cities
Phoenix, Arizona • La Jolla, California • Mountain View, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Jul 21, 2026, 7:38 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion

NCT04740905
View directory record Official record
Conditions
Macular Edema, Branch Retinal Vein Occlusion
Interventions
Faricimab, Aflibercept, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
39
States / cities
Phoenix, Arizona • Tucson, Arizona • Campbell, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Jul 21, 2026, 7:38 PM EDT
Completed Phase 4 Interventional

Ocular Safety and Usability Study for FYB203 PFS

NCT06708637
View directory record Official record
Conditions
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema, Diabetic Macular Edema, Diabetic Retinopathy
Interventions
FYB203 2 mg (0.05 mL of 40 mg/mL)
Drug
Lead sponsor
Formycon AG
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
4
States / cities
Campbell, California • Long Beach, California • Redlands, California + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Jul 21, 2026, 7:38 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration

NCT06664502
View directory record Official record
Conditions
Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (NVAMD), BRVO - Branch Retinal Vein Occlusion
Interventions
EYE201
Drug
Lead sponsor
EyeBiotech Ltd.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
26
States / cities
Scottsdale, Arizona • Modesto, California • Mountain View, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jul 21, 2026, 7:38 PM EDT
Completed Phase 3 Interventional Results available

The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study

NCT00105027
View directory record Official record
Conditions
Macular Edema, Cystoid, Retinal Vein Occlusion
Interventions
Standard Care, intravitreal triamcinolone injection
Other · Drug
Lead sponsor
The Emmes Company, LLC
Industry
Eligibility
18 Years and older
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Jul 21, 2026, 7:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab

NCT01471691
View directory record Official record
Conditions
Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Macular Edema
Interventions
ranibizumab 0.5mg, ranibizumab 1.0mg
Drug
Lead sponsor
Hanscom, Thomas, M.D.
Individual
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
4
States / cities
Huntington Beach, California • Long Beach, California • Santa Monica, California + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Jul 21, 2026, 7:38 PM EDT
Active, not recruiting Phase 3 Interventional

A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders

NCT05112861
View directory record Official record
Conditions
Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
bevacizumab
Biological
Lead sponsor
Outlook Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Springfield, Illinois • Hagerstown, Maryland • Chambersburg, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 21, 2026, 7:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Pilot Study of Functional Optical Coherence Tomography for Ocular Imaging

NCT00556114
View directory record Official record
Conditions
Glaucoma, Diabetic Retinopathy, Age-Related Macular Degeneration, Central Retinal Vein Occlusion, Branch Retinal Vein Occlusion
Interventions
Optical Coherence Tomography
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Jul 21, 2026, 7:38 PM EDT
Terminated Phase 3 Interventional Results available

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion

NCT03802630
View directory record Official record
Conditions
Branch Retinal Vein Occlusion
Interventions
Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
26
States / cities
Phoenix, Arizona • Mountain View, California • Santa Barbara, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Jul 21, 2026, 7:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Minocycline to Treat Branch Retinal Vein Occlusion

NCT01468831
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Minocycline, Placebo, Bevacizumab
Drug · Other
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Jul 21, 2026, 7:38 PM EDT
Not listed Not applicable Interventional

A Research Study to Evaluate the Effects of Repeated Intravitreal Injections on Bacteria Around the Eye

NCT01531842
View directory record Official record
Conditions
Central Retinal Vein Occlusion, Choroidal Neovascularization, Age-related Macular Degeneration, Branch Retinal Vein Occlusion
Interventions
Conj flora Antibiotic resistance
Procedure
Lead sponsor
Mid Atlantic Retina
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2012 · Synced Jul 21, 2026, 7:38 PM EDT
Completed Phase 3 Interventional Results available

A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)

NCT02698566
View directory record Official record
Conditions
Macular Edema
Interventions
Ranibizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Paducah, Kentucky • Charlotte, North Carolina • Chattanooga, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Jul 21, 2026, 7:38 PM EDT